Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2007 5
2008 5
2010 5
2011 5
2012 2
2014 1
2015 1
2016 2
2017 2
2018 7
2019 5
2020 5
2021 6
2022 6
2023 7
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

59 results

Results by year

Filters applied: . Clear all
Page 1
Risk Factors for Meeting Criteria for Switching from Bevacizumab to Aflibercept When Treating Eyes with Diabetic Macular Edema and Visual Acuity of < 20/40.
Jhaveri CD, Liu D, Maguire MG, Glassman AR, Grigorian RA, Jampol LM, Kingsley RM, MacCumber MW, Martin DF, Maturi RK, Velez G, Sun JK; DRCR Retina Network. Jhaveri CD, et al. Ophthalmology. 2024 Feb 8:S0161-6420(24)00098-8. doi: 10.1016/j.ophtha.2024.01.037. Online ahead of print. Ophthalmology. 2024. PMID: 38336282
Imaging Modalities for Assessing the Vascular Component of Diabetic Retinal Disease: Review and Consensus for an Updated Staging System.
Tan TE, Jampol LM, Ferris FL, Tadayoni R, Sadda SR, Chong V, Domalpally A, Blodi BL, Duh EJ, Curcio CA, Antonetti DA, Dutta S, Levine SR, Sun JK, Gardner TW, Wong TY. Tan TE, et al. Ophthalmol Sci. 2023 Dec 10;4(3):100449. doi: 10.1016/j.xops.2023.100449. eCollection 2024 May-Jun. Ophthalmol Sci. 2023. PMID: 38313399 Free PMC article.
Changes in activity impairment and work productivity after treatment for vitreous hemorrhage due to proliferative diabetic retinopathy: Secondary outcomes from a randomized controlled trial (DRCR Retina Network Protocol AB).
Beaulieu WT, Maguire MG, Antoszyk AN; DRCR Retina Network. Beaulieu WT, et al. PLoS One. 2023 Nov 16;18(11):e0293543. doi: 10.1371/journal.pone.0293543. eCollection 2023. PLoS One. 2023. PMID: 37972038 Free PMC article. Clinical Trial.
Four-Year Visual Outcomes in the Protocol W Randomized Trial of Intravitreous Aflibercept for Prevention of Vision-Threatening Complications of Diabetic Retinopathy.
Maturi RK, Glassman AR, Josic K, Baker CW, Gerstenblith AT, Jampol LM, Meleth A, Martin DF, Melia M, Punjabi OS, Rofagha S, Salehi-Had H, Stockdale CR, Sun JK; DRCR Retina Network. Maturi RK, et al. JAMA. 2023 Feb 7;329(5):376-385. doi: 10.1001/jama.2022.25029. JAMA. 2023. PMID: 36749332 Free PMC article.
Association of Ultra-Widefield Fluorescein Angiography-Identified Retinal Nonperfusion and the Risk of Diabetic Retinopathy Worsening Over Time.
Silva PS, Marcus DM, Liu D, Aiello LP, Antoszyk A, Elman M, Friedman S, Glassman AR, Googe JM, Jampol LM, Martin DF, Melia M, Preston CM, Wykoff CC, Sun JK; DRCR Retina Network. Silva PS, et al. JAMA Ophthalmol. 2022 Oct 1;140(10):936-945. doi: 10.1001/jamaophthalmol.2022.3130. JAMA Ophthalmol. 2022. PMID: 35980610 Free PMC article.
Association of Predominantly Peripheral Lesions on Ultra-Widefield Imaging and the Risk of Diabetic Retinopathy Worsening Over Time.
Marcus DM, Silva PS, Liu D, Aiello LP, Antoszyk A, Elman M, Friedman S, Glassman AR, Googe JM, Jampol LM, Martin DF, Melia M, Preston CM, Wykoff CC, Sun JK; DRCR Retina Network. Marcus DM, et al. JAMA Ophthalmol. 2022 Oct 1;140(10):946-954. doi: 10.1001/jamaophthalmol.2022.3131. JAMA Ophthalmol. 2022. PMID: 35980608 Free PMC article.
59 results